We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Maelor | LSE:MLR | London | Ordinary Share | GB00B2QBY649 | ORD 70P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 100.00 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:1874W Maelor PLC 08 May 2007 8 May 2007 Maelor plc ("Maelor" or the "Company") Re-Admission, Conditional Placing and Acquisition The Board of Maelor plc (AIM: MLR), the specialist critical care company, is pleased to announce that it has conditionally raised #8 million through a placing of 80,000,000 new ordinary shares of 10p (the "Placing") by Noble & Company Limited, Maelor's nominated adviser and broker. Geoff McMillan, Non-Executive Chairman, Tim Wright, Chief Executive Officer, Nigel Goldsmith, Finance Director, Ann Hardy, Executive Director and John Gregory, Non-Executive Director have all participated in the Placing. First Admission and the commencement of dealings in relation to the 70,005,833 Existing Ordinary Shares and New VCT/EIS Shares will take place today. It is expected that Second Admission and the commencement of dealings in relation to the 44,275,000 Protected VCT Shares and Non-VCT Shares will occur at 8am on 9 May 2007 and that Third Admission and commencement of dealings in relation to 10,000,000 Consideration Shares will occur at 8am on 10 May 2007. It is expected that completion of the acquisition of Acorus Therapeutics Limited will occur immediately following Third Admission. Following completion of the acquisition of Acorus Therapeutics Limited, the Company will have 124,280,833 ordinary shares of 10p in issue. Tim Wright, CEO of Maelor said: "The acquisition of Acorus is a transforming transaction for Maelor, creating a strong, profitable business with positive cash flow. The integration risks, costs and distractions are minimal due to the virtual nature of Acorus and the combined product portfolios offer a high degree of synergy in terms of customer base and distribution channels. We now have a product portfolio and pipeline capable of delivering strong future growth." - Ends - For further information, call: Maelor plc Tim Wright - 01244 625150 Noble & Company Limited Matthew Hall/Sam Reynolds - 020 7763 2200 Financial Dynamics Billy Clegg/Edward Westropp - 020 7831 3113 This information is provided by RNS The company news service from the London Stock Exchange END MSCUBARRBURVRUR
1 Year Maelor Chart |
1 Month Maelor Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions